Literature DB >> 7348564

Correlation of primary breast cancer histopathology and estrogen receptor content.

E R Fisher, C K Osborne, W L McGuire, C Redmond, W A Knight, B Fisher, G Bannayan, A Walder, E J Gregory, A Jacobsen, D M Queen, D E Bennett, H C Ford.   

Abstract

We studied the association of estrogen receptor (ER) with several histologic variables that correlate with breast tumor differentiation and with patient prognosis. Contingency table analysis revealed highly statistically significant correlations between ER content and histologic and nuclear grades, tumor necrosis, and the degree of elastosis and lymphoid cell infiltration. ER positive tumors were more likely than ER negative tumors to demonstrate histological evidence of tumor differentiation. All tumors with histologic grade 1 or nuclear grade 1 (best differentiated) were ER positive or borderline positive. Eighty-nine percent of ER negative tumors were histologic grade 3 and 78.4% were nuclear grade 3 (poor differentiation). ER positive tumors were also correlated with absent tumor necrosis, higher elastic content, and absent lymphoid cell infiltration, all features of good differentiation. Medullary carcinomas were frequently (73%) ER negative, but no relationship between ER and other morphologic types of breast cancer or 9 other morphologic variables was found. ER appears to be a biochemical marker for the degree of differentiation of human breast cancer providing a rationale for the observed differences in biological behavior between receptor positive and negative tumors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7348564     DOI: 10.1007/bf01807890

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

1.  Pathologic findings from the national surgical adjuvant breast project (protocol no. 4). II. The significance of regional node histology other than sinus histiocytosis in invasive mammary cancer.

Authors:  E R Fisher; R Gregorio; C Redmond; A Dekker; B Fisher
Journal:  Am J Clin Pathol       Date:  1976-01       Impact factor: 2.493

2.  The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4).

Authors:  E R Fisher; R M Gregorio; B Fisher; C Redmond; F Vellios; S C Sommers
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

3.  Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication.

Authors:  J S Meyer; B R Rao; S C Stevens; W L White
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

4.  Prognostic value of estrogen receptor determinations in patients with breast cancer.

Authors:  M A Rich; P Furmanski; S C Brooks
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

5.  Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer.

Authors:  E R Fisher; C K Redmond; H Liu; H Rockette; B Fisher
Journal:  Cancer       Date:  1980-01-15       Impact factor: 6.860

6.  Relationship of oestrogen-receptor status to survival in breast cancer.

Authors:  H M Bishop; R W Blamey; C W Elston; J L Haybittle; R I Nicholson; K Griffiths
Journal:  Lancet       Date:  1979-08-11       Impact factor: 79.321

7.  Modern approaches to the treatment of breast cancer.

Authors:  C K Osborne; W A Knight; M G Yochmowitz; W L McGuire
Journal:  Blood       Date:  1980-11       Impact factor: 22.113

8.  The surgical implications of estrophile protein estimations in carcinoma of the breast.

Authors:  A J Walt; A Singhakowinta; S C Brooks; A Cortez
Journal:  Surgery       Date:  1976-10       Impact factor: 3.982

9.  Relationship between proliferative activity and estrogen receptors in breast cancer.

Authors:  R Silverstrini; M G Daidone; G Di Fronzo
Journal:  Cancer       Date:  1979-08       Impact factor: 6.860

10.  Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol no. 4). VI. Discriminants for five-year treatment failure.

Authors:  E R Fisher; C Redmond; B Fisher
Journal:  Cancer       Date:  1980-08-15       Impact factor: 6.860

View more
  16 in total

1.  Correlation of Hormone Receptor Expression with Histologic Parameters in Benign and Malignant Breast Tumors.

Authors:  Deepti Gupta; Veena Gupta; Nisha Marwah; Meenu Gill; Sumiti Gupta; Gopal Gupta; Promil Jain; Rajeev Sen
Journal:  Iran J Pathol       Date:  2015

2.  Clinicopathological value of somatostatin type 2A and estrogen receptor immunoreactivity in human breast carcinoma.

Authors:  M Pilichowska; N Kimura; A Suzuki; R Yoshida; M Schindler; H Nagura
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

3.  Oestrogen receptor activity in intraduct and invasive breast carcinomas.

Authors:  R A Hawkins; A L Tesdale; W A Ferguson; J J Going
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

4.  Tumor nuclear grade, estrogen receptor, and progesterone receptor: their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer.

Authors:  B Fisher; E R Fisher; C Redmond; A Brown
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

5.  Oestrogen and progesterone receptor content and the distribution of histological grade in breast cancer.

Authors:  S Thoresen; T Thorsen; M Tangen; F Hartveit
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

6.  Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model.

Authors:  C K Osborne; C R Ross; E B Coronado; S A Fuqua; L J Kitten
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

7.  Relation of elastosis to biochemical and immunohistochemical steroid receptor findings, Ki-67 and epidermal growth factor receptor (EGFR) immunostaining in invasive ductal breast cancer.

Authors:  W Remmele; M Dietz; F Schmidt; K H Schicketanz
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  The relationship of estrogen receptor status to DNA ploidy in breast cancer.

Authors:  A Tsuchiya; M Nihei; Y Ando; S Suzuki; I Kimijima; R Abe
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

9.  Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients.

Authors:  J Lundy; A Thor; R Maenza; J Schlom; F Forouhar; M Testa; D Kufe
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

10.  Response to endocrine therapy and breast cancer differentiation.

Authors:  J R Masters; R R Millis; R D Rubens
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.